Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 79-90

  Thirant, Cécile ^a   Gavard, Julie ^b   Junier, Marie Pierre ^c   Chneiweiss, Hervé ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUT COCHIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anti angiogenic; Endothelial cell; Glioblastoma stem like cells; HDGF; Therapeutic resistance

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; CD133 ANTIGEN; CD15 ANTIGEN; CEDIRANIB; DLL 4; HEPATOMA DERIVED GROWTH FACTOR; MICRORNA; NOTCH RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE 2; SEMAPHORIN 3A; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL GROWTH; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; GLIOBLASTOMA; GLIOBLASTOMA STEM LIKE CELL; HUMAN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; GLIOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASTIC STEM CELLS;

EID: 84872728358     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200102     Document Type: Review

References (153)

1. Dufour, C., Cadusseau, J., Varlet, P., Surena, A. et al., Astrocytes reverted to a neural progenitor-like state with transforming growth factor alpha (TGFalpha) are sensitized to cancerous transformation. Stem Cells 2009, 27, 2373-2382.
2. Siebzehnrubl, F. A., Reynolds, B. A., Vescovi, A., Steindler, D. A., Deleyrolle, L. P., The origins of glioma: E pluribus unum? Glia 2011, 59, 1135-1147.
3. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M. et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
4. Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J. et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459-466.
5. Stupp, R., Hegi, M., Weller, M., Neuro-oncology, a decade of temozolomide and beyond. Expert Rev. Anticancer Ther. 2010, 10, 1675-1677.
6. Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R. et al., Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 2008, 14, 2900-2908.
7. Reya, T., Morrison, S. J., Clarke, M. F., Weissman, I. L., Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
8. Visvader, J. E., Lindeman, G. J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755-768.
9. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A. et al., Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401.
10. Galli, R., Binda, E., Orfanelli, U., Cipelletti, B. et al., Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64, 7011-7021.
11. Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E. et al., Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
12. Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M. et al., Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003, 100, 15178-15183.
13. Patru, C., Romao, L., Varlet, P., Coulombel, L. et al., CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 2010, 10, 66-77.
14. Thirant, C., Bessette, B., Varlet, P., Puget, S. et al., Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS One 2011, 6, e16375.
15. Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M. et al., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468, 824-828.
16. Bao, S., Wu, Q., McLendon, R. E., Hao, Y. et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756-760.
17. Facchino, S., Abdouh, M., Chatoo, W., Bernier, G., BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J. Neurosci. 2010, 30, 10096-10111.
18. Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B. et al., Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28, 17-28.
19. Lomonaco, S. L., Finniss, S., Xiang, C., Decarvalho, A. et al., The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int. J. Cancer 2009, 125, 717-722.
20. Zhuang, W., Li, B., Long, L., Chen, L. et al., Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int. J. Cancer 2011, 129, 2720-2731.
21. Kang, M. K., Kang, S. K., Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 2007, 16, 837-847.
22. Liu, G., Black, K. L., Yu, J. S., Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev. Vaccines 2006, 5, 233-247.
23. Everett, A. D., Stoops, T., McNamara, C. A., Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J. Biol. Chem. 2001, 276, 37564-37568.
24. Chen, J., Li, Y., Yu, T. S., McKay, R. M. et al., A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488, 522-526.
25. Zagzag, D., Esencay, M., Mendez, O., Yee, H. et al., Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 2008, 173, 545-560.
26. Hoelzinger, D. B., Demuth, T., Berens, M. E., Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl. Cancer Inst. 2007, 99, 1583-1593.
27. Gondi, C. S., Lakka, S. S., Dinh, D. H., Olivero, W. C. et al., Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin. Cancer Res. 2007, 13, 4051-4060.
28. Raghu, H., Lakka, S. S., Gondi, C. S., Mohanam, S. et al., Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One 2010, 5, e12458.
29. Page-McCaw, A., Ewald, A. J., Werb, Z., Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221-233.
30. Dunn, J. R., Reed, J. E., du Plessis, D. G., Shaw, E. J. et al., Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br. J. Cancer 2006, 94, 1186-1193.
31. Lucio-Eterovic, A. K., Piao, Y., de Groot, J. F., Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 2009, 15, 4589-4599.
32. Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K. et al., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114, 97-109.
33. Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S. et al., Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007, 8, 610-622.
34. Yin, S., Kaluz, S., Devi, N. S., Jabbar, A. A. et al., Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1alpha interaction with co-factors p300/CBP. Clin. Cancer Res. 2012, 18, 6623-6633.
35. Keith, B., Simon, M. C., Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129, 465-472.
36. Li, Z., Bao, S., Wu, Q., Wang, H. et al., Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15, 501-513.
37. Qiang, L., Wu, T., Zhang, H. W., Lu, N. et al., HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 2012, 19, 284-294.
38. Seidel, S., Garvalov, B. K., Wirta, V., von Stechow, L. et al., A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133, 983-995.
39. Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., Rich, J. N., The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8, 3274-3284.
40. Heddleston, J. M., Wu, Q., Rivera, M., Minhas, S. et al., Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012, 19, 428-439.
41. Christensen, K., Schroder, H. D., Kristensen, B. W., CD133 identifies perivascular niches in grade II-IV astrocytomas. J. Neurooncol. 2008, 90, 157-170.
42. Venere, M., Fine, H. A., Dirks, P. B., Rich, J. N., Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia 2011, 59, 1148-1154.
43. Ping, Y. F., Yao, X. H., Jiang, J. Y., Zhao, L. T. et al., The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J. Pathol. 2011, 224, 344-354.
44. Jin, X., Yin, J., Kim, S. H., Sohn, Y. W. et al., EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011, 71, 7125-7134.
45. Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U. et al., Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468, 829-833.
46. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M. et al., Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA 2011, 108, 4274-4280.
47. Mellinghoff, I. K., Lassman, A. B., Wen, P. Y., Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 2011, 59, 1205-1212.
48. Reardon, D. A., Turner, S., Peters, K. B., Desjardins, A. et al., A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J. Natl. Compr. Canc. Netw. 2011, 9, 414-427.
49. Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T. et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27, 4733-4740.
50. Kreisl, T. N., Kim, L., Moore, K., Duic, P. et al., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27, 740-745.
51. Norden, A. D., Drappatz, J., Wen, P. Y., Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008, 7, 1152-1160.
52. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A. et al., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15, 232-239.
53. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T. et al., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15, 220-231.
54. Khasraw, M., Lassman, A. B., Advances in the treatment of malignant gliomas. Curr. Oncol. Rep. 2010, 12, 26-33.
55. de Groot, J. F., Fuller, G., Kumar, A. J., Piao, Y. et al., Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro. Oncol. 2010, 12, 233-242.
56. di Tomaso, E., Snuderl, M., Kamoun, W. S., Duda, D. G. et al., Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011, 71, 19-28.
57. Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R. et al., Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18, 510-523.
58. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E. et al., A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141, 583-594.
59. Lee, J., Kotliarova, S., Kotliarov, Y., Li, A. et al., Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9, 391-403.
60. Gunther, H. S., Schmidt, N. O., Phillips, H. S., Kemming, D. et al., Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008, 27, 2897-2909.
61. + glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J. Neurooncol. 2009, 94, 1-19.
62. Silvestre, D. C., Pineda, J. R., Hoffschir, F., Studler, J. M. et al., Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 2011, 29, 440-451.
63. Fareh, M., Turchi, L., Virolle, V., Debruyne, D. et al., The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2012, 19, 232-244.
64. Hjelmeland, A. B., Wu, Q., Heddleston, J. M., Choudhary, G. S. et al., Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011, 18, 829-840.
65. Tavazoie, M., Van der Veken, L., Silva-Vargas, V., Louissaint, M. et al., A specialized vascular niche for adult neural stem cells. Cell Stem Cell 2008, 3, 279-288.
66. Gomez-Gaviro, M. V., Scott, C. E., Sesay, A. K., Matheu, A. et al., Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis. Proc. Natl. Acad. Sci. USA 2012, 109, 1317-1322.
67. Thirant, C., Galan-Moya, E. M., Dubois, L. G., Pinte, S. et al., Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells 2012, 30, 845-853.
68. Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V. et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98-110.
69. Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F. et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157-173.
70. Szerlip, N. J., Pedraza, A., Chakravarty, D., Azim, M. et al., Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 2012, 109, 3041-3046.
71. Kim, Y., Kim, E., Wu, Q., Guryanova, O. et al., Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 2012, 26, 1247-1262.
72. Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M. et al., Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20, 810-817.
73. Bonavia, R., Inda, M. M., Cavenee, W. K., Furnari, F. B., Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011, 71, 4055-4060.
74. Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L. et al., A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69-82.
75. Lathia, J. D., Gallagher, J., Heddleston, J. M., Wang, J. et al., Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6, 421-432.
76. Folkins, C., Man, S., Xu, P., Shaked, Y. et al., Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007, 67, 3560-3564.
77. Charles, N., Ozawa, T., Squatrito, M., Bleau, A. M. et al., Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6, 141-152.
78. Eyler, C. E., Wu, Q., Yan, K., MacSwords, J. M. et al., Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011, 146, 53-66.
79. Zhu, T. S., Costello, M. A., Talsma, C. E., Flack, C. G. et al., Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 2011, 71, 6061-6072.
80. Hovinga, K. E., Shimizu, F., Wang, R., Panagiotakos, G. et al., Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010, 28, 1019-1029.
81. Dai, L., He, J., Liu, Y., Byun, J. et al., Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with gamma-secretase inhibitor. Proteomics 2011, 11, 4529-4540.
82. Fan, X., Khaki, L., Zhu, T. S., Soules, M. E. et al., NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28, 5-16.
83. Li, J. L., Sainson, R. C., Oon, C. E., Turley, H. et al., DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011, 71, 6073-6083.
84. Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P. et al., Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463, E6-E7.
85. Hoey, T., Yen, W. C., Axelrod, F., Basi, J. et al., DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5, 168-177.
86. Fischer, M., Yen, W. C., Kapoun, A. M., Wang, M. et al., Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 2011, 71, 1520-1525.
87. Weksler, B. B., Subileau, E. A., Perriere, N., Charneau, P. et al., Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19, 1872-1874.
88. Galan-Moya, E. M., Le Guelte, A., Lima Fernandes, E., Thirant, C. et al., Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep. 2011, 12, 470-476.
89. Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J. et al., Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108, 7950-7955.
90. Vermeulen, L., De Sousa, E. M. F., van der Heijden, M., Cameron, K. et al., Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468-476.
91. Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y. et al., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66, 7843-7848.
92. Hamerlik, P., Lathia, J. D., Rasmussen, R., Wu, Q. et al., Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med. 2012, 209, 507-520.
93. Yang, S. X., Chen, J. H., Jiang, X. F., Wang, Q. L. et al., Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 2005, 335, 523-528.
94. El Hallani, S., Boisselier, B., Peglion, F., Rousseau, A. et al., A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010, 133, 973-982.
95. Jain, R. K., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
96. Jain, R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62.
97. Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W. T. et al., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11, 83-95.
98. Sorensen, A. G., Emblem, K. E., Polaskova, P., Jennings, D. et al., Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012, 72, 402-407.
99. Aird, W. C., Endothelial cell heterogeneity. Cold Spring Harb. Perspect. Med. 2012, 2, a006429.
100. Chi, J. T., Chang, H. Y., Haraldsen, G., Jahnsen, F. L. et al., Endothelial cell diversity revealed by global expression profiling. Proc. Natl. Acad. Sci. USA 2003, 100, 10623-10628.
101. Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M. et al., Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 2007, 6, 650-661.
102. Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
103. Cao, Y., Off-tumor target-beneficial site for antiangiogenic cancer therapy? Nat. Rev. Clin. Oncol. 2010, 7, 604-608.
104. Olsson, A. K., Dimberg, A., Kreuger, J., Claesson-Welsh, L., VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7, 359-371.
105. Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M. et al., A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456, 809-813.
106. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H. et al., Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996, 56, 2185-2190.
107. Nam, D. H., Park, K., Suh, Y. L., Kim, J. H., Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol. Rep. 2004, 11, 863-869.
108. Norden, A. D., Drappatz, J., Wen, P. Y., Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol. 2009, 5, 610-620.
109. Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M. et al., Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 2010, 28, 2817-2823.
110. Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M. et al., Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 2009, 27, 2542-2552.
111. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C. et al., Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134.
112. Neyns, B., Sadones, J., Chaskis, C., Dujardin, M. et al., Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol. 2011, 103, 491-501.
113. Moreno Garcia, V., Basu, B., Molife, L. R., Kaye, S. B., Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin. Cancer Res 2012, 18, 3750-3761.
114. Vredenburgh, J. J., Desjardins, A., Herndon, J. E., 2nd, Dowell, J. M. et al., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13, 1253-1259.
115. Poulsen, H. S., Grunnet, K., Sorensen, M., Olsen, P. et al., Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009, 48, 52-58.
116. Hattingen, E., Jurcoane, A., Bahr, O., Rieger, J. et al., Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro. Oncol. 2011, 13, 1349-1363.
117. Moller, S., Grunnet, K., Hansen, S., Schultz, H. et al., A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012, 51, 797-804.
118. Fraum, T. J., Kreisl, T. N., Sul, J., Fine, H. A., Iwamoto, F. M., Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J. Neurooncol. 2011, 105, 281-289.
119. von Baumgarten, L., Brucker, D., Tirniceru, A., Kienast, Y. et al., Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin. Cancer Res. 2011, 17, 6192-6205.
120. Reardon, D. A., Desjardins, A., Peters, K. B., Gururangan, S. et al., Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J. Neurooncol. 2012, 107, 155-164.
121. Vredenburgh, J. J., Desjardins, A., Reardon, D. A., Peters, K. B. et al., The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res. 2011, 17, 4119-4124.
122. Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M. et al., VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22, 21-35.
123. Gherardi, E., Birchmeier, W., Birchmeier, C., Vande Woude, G., Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12, 89-103.
124. Hu, B., Guo, P., Bar-Joseph, I., Imanishi, Y. et al., Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007, 26, 5577-5586.
125. Surena, A. L., de Faria, G. P., Studler, J. M., Peiretti, F. et al., DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochim. Biophys. Acta 2009, 1793, 264-272.
126. Terasaki, M., Sugita, Y., Arakawa, F., Okada, Y. et al., CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol. 2011, 28, 89-97.
127. Folkins, C., Shaked, Y., Man, S., Tang, T. et al., Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 2009, 69, 7243-7251.
128. Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S. et al., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68, 4774-4782.
129. Le Guelte, A., Galan-Moya, E. M., Dwyer, J., Treps, L., et al., Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J. Cell Sci. 2012, 125, 4137-4146.
130. Maione, F., Molla, F., Meda, C., Latini, R. et al., Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119, 3356-3372.
131. Bagci, T., Wu, J. K., Pfannl, R., Ilag, L. L., Jay, D. G., Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene 2009, 28, 3537-3550.
132. Casazza, A., Fu, X., Johansson, I., Capparuccia, L. et al., Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 741-749.
133. Chakraborty, G., Kumar, S., Mishra, R., Patil, T. V., Kundu, G. C., Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One 2012, 7, e33633.
134. Maione, F., Capano, S., Regano, D., Zentilin, L. et al., Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 2012, 122, 1832-1848.
135. Klagsbrun, M., Sasse, J., Sullivan, R., Smith, J. A., Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 1986, 83, 2448-2452.
136. Everett, A. D., Lobe, D. R., Matsumura, M. E., Nakamura, H., McNamara, C. A., Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J. Clin. Invest. 2000, 105, 567-575.
137. Enomoto, H., Yoshida, K., Kishima, Y., Kinoshita, T. et al., Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002, 36, 1519-1527.
138. von Heijne, G., A new method for predicting signal sequence cleavage sites. Nucleic Acids Res. 1986, 14, 4683-4690.
139. Thakar, K., Krocher, T., Savant, S., Gollnast, D. et al., Secretion of hepatoma-derived growth factor is regulated by N-terminal processing. Biol. Chem. 2010, 391, 1401-1410.
140. Abouzied, M. M., El-Tahir, H. M., Prenner, L., Haberlein, H. et al., Hepatoma-derived growth factor. Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity. J. Biol. Chem. 2005, 280, 10945-10954.
141. Okuda, Y., Nakamura, H., Yoshida, K., Enomoto, H. et al., Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003, 94, 1034-1041.
142. Ren, H., Chu, Z., Mao, L., Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol. Cancer Ther. 2009, 8, 1106-1112.
143. Everett, A. D., Narron, J. V., Stoops, T., Nakamura, H., Tucker, A., Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L1194-1201.
144. Abouzied, M. M., Baader, S. L., Dietz, F., Kappler, J. et al., Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem. J. 2004, 378, 169-176.
145. Kishima, Y., Yamamoto, H., Izumoto, Y., Yoshida, K. et al., Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J. Biol. Chem. 2002, 277, 10315-10322.
146. Hsu, S. S., Chen, C. H., Liu, G. S., Tai, M. H. et al., Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J. Neurooncol. 2012, 107, 101-109.
147. Zhao, J., Yu, H., Lin, L., Tu, J. et al., Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J. Proteomics 2011, 75, 588-602.
148. Sedlmaier, A., Wernert, N., Gallitzendorfer, R., Abouzied, M. M. et al., Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation. BMC Cancer 2011, 11, 457-461.
149. Shapiro, J. R., Yung, W. K., Shapiro, W. R., Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res. 1981, 41, 2349-2359.
150. Thirant, C., Varlet, P., Lipecka, J., Le Gall, M. et al., Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. Proteomics 2011, 11, 4139-4154.
151. Gollapalli, K., Ray, S., Srivastava, R., Renu, D. et al., Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 2012, 12, 2378-2390.
152. Mustafa, D. A., Dekker, L. J., Stingl, C., Kremer, A. et al., A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma. Mol. Cell. Proteomics 2012, 11, M111 008466.
153. Kozuka-Hata, H., Nasu-Nishimura, Y., Koyama-Nasu, R., Ao-Kondo, H. et al., Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome. PLoS One 2012, 7, e43398.